Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.23736/S2724-5985.20.02771-3 http://scihub22266oqcxt.onion/10.23736/S2724-5985.20.02771-3 33016666!ä!33016666 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33016666&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Minerva+Gastroenterol+(Torino) 2021 ; 67 (2): 190-195 Nephropedia Template TP {{tp|p=33016666|t=2021. Quercetin Phytosome(R) as a potential candidate for managing COVID-19 |pdf=|usr=}}{{33016666}} gab.com Text Quercetin Phytosome(R) as a potential candidate for managing COVID-19 JO: Minerva Gastroenterol (Torino) http://www.kidney.de/pget.php?&tw=1&pmid=33016666 #FOAvip When looking for new antiviral compounds aimed to counteract the COVID-19, a disease caused by the recently identified novel Coronavirus (SARS-CoV-2), the knowledge of the main viral proteins is fundamental. The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) protein. Molecular docking studies have highlighted that quercetin, a natural polyphenol belonging to the flavonol class, inhibits 3CLpro, PLpro and S proteins. Biophysical technics have then very recently confirmed that quercetin is reasonably a potent inhibitor of 3CLpro. The likely antiviral properties of quercetin are anyway challenged by its very poor oral bioavailability profile and any attempt to overcome this limit should be welcome. A phospholipid delivery form of quercetin (Quercetin Phytosome((R))) has been recently tested in humans to evaluate a possible improvement in oral bioavailability. After hydrolysis of the conjugated form (mainly glucuronide) of quercetin found in human plasma, the pharmacokinetics results have demonstrated an increased bioavailability rate by about 20-fold for total quercetin. It has been also observed that the presence of specific glucuronidase could yield free systemic quercetin in human body. Taking also into considerations its anti-inflammatory and thrombin-inhibitory actions, a bioavailable form of quercetin, like Quercetin Phytosome((R)), should be considered a possible candidate to clinically face COVID-19. Twit Text FOAVip Quercetin Phytosome(R) as a potential candidate for managing COVID-19 ????Minerva Gastroenterol (Torino) http://www.kidney.de/pget.php?&tw=1&pmid=33016666 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33016666 #FOAvip English Wikipedia <ref>{{Cite pmid|33016666}}</ref> Quercetin Phytosome(R) as a potential candidate for managing COVID-19 #MMPMID33016666 DI Pierro F; Khan A; Bertuccioli A; Maffioli P; Derosa G; Khan S; Khan BA; Nigar R; Ujjan I; Devrajani BR Minerva Gastroenterol (Torino) 2021[Jun]; 67 (2): 190-195 PMID33016666show ga When looking for new antiviral compounds aimed to counteract the COVID-19, a disease caused by the recently identified novel Coronavirus (SARS-CoV-2), the knowledge of the main viral proteins is fundamental. The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) protein. Molecular docking studies have highlighted that quercetin, a natural polyphenol belonging to the flavonol class, inhibits 3CLpro, PLpro and S proteins. Biophysical technics have then very recently confirmed that quercetin is reasonably a potent inhibitor of 3CLpro. The likely antiviral properties of quercetin are anyway challenged by its very poor oral bioavailability profile and any attempt to overcome this limit should be welcome. A phospholipid delivery form of quercetin (Quercetin Phytosome((R))) has been recently tested in humans to evaluate a possible improvement in oral bioavailability. After hydrolysis of the conjugated form (mainly glucuronide) of quercetin found in human plasma, the pharmacokinetics results have demonstrated an increased bioavailability rate by about 20-fold for total quercetin. It has been also observed that the presence of specific glucuronidase could yield free systemic quercetin in human body. Taking also into considerations its anti-inflammatory and thrombin-inhibitory actions, a bioavailable form of quercetin, like Quercetin Phytosome((R)), should be considered a possible candidate to clinically face COVID-19. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/therapeutic use[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH]Quercetin Phytosome(R) as a potential candidate for managing COVID-19 (epmc).pdf DeepDyve Pubget Overpricing